Sigma Planning Corp Acquires 3,327 Shares of Illumina, Inc. $ILMN

Sigma Planning Corp grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 91.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,980 shares of the life sciences company’s stock after acquiring an additional 3,327 shares during the quarter. Sigma Planning Corp’s holdings in Illumina were worth $1,910,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Baker Tilly Wealth Management LLC boosted its stake in Illumina by 3.3% in the 3rd quarter. Baker Tilly Wealth Management LLC now owns 1,297 shares of the life sciences company’s stock worth $355,000 after purchasing an additional 42 shares in the last quarter. Elevation Wealth Partners LLC grew its position in Illumina by 19.7% during the 3rd quarter. Elevation Wealth Partners LLC now owns 292 shares of the life sciences company’s stock worth $80,000 after purchasing an additional 48 shares during the last quarter. Evergreen Capital Management LLC grew its position in Illumina by 0.5% during the 3rd quarter. Evergreen Capital Management LLC now owns 9,474 shares of the life sciences company’s stock worth $2,593,000 after purchasing an additional 50 shares during the last quarter. Pinnacle Associates Ltd. increased its stake in Illumina by 2.2% during the 3rd quarter. Pinnacle Associates Ltd. now owns 2,506 shares of the life sciences company’s stock valued at $686,000 after purchasing an additional 54 shares in the last quarter. Finally, IFP Advisors Inc increased its stake in Illumina by 2.9% during the 3rd quarter. IFP Advisors Inc now owns 1,986 shares of the life sciences company’s stock valued at $544,000 after purchasing an additional 56 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Canaccord Genuity Group lifted their price objective on shares of Illumina from $205.00 to $300.00 and gave the stock a “hold” rating in a research note on Monday, October 19th. Guggenheim upped their target price on Illumina from $226.00 to $305.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Argus raised their target price on Illumina from $180.00 to $235.00 and gave the stock a “buy” rating in a research note on Thursday, September 3rd. Sanford C. Bernstein restated a “market perform” rating and issued a $215.00 target price on shares of Illumina in a research note on Friday, July 31st. Finally, JPMorgan Chase & Co. boosted their price target on Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Ten research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $234.41.

Illumina Stock Performance

Shares of ILMN opened at $279.47 on Wednesday. Illumina, Inc. has a 52 week low of $94.00 and a 52 week high of $309.35. The stock’s 50-day moving average price is $245.13 and its 200-day moving average price is $174.27.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.23 by $0.08. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. The firm’s revenue was up 9.4% on a year-over-year basis. During the same period last year, the business earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts predict that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Insider Activity at Illumina

In other news, SVP Christensen Wedel sold 1,033 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the sale, the senior vice president owned 14,023 shares of the company’s stock, valued at $2,685,684.96. This trade represents a 6.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith Meister sold 119,501 shares of Illumina stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the transaction, the director directly owned 770,350 shares of the company’s stock, valued at approximately $168,244,440. This trade represents a 13.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 2,061,850 shares of company stock worth $436,479,102. Insiders own 2.90% of the company’s stock.

Illumina Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.